BioPharma Dive – AI / Data

Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases

Published

2 weeks ago

on

Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version